Journal of International Oncology››2013,Vol. 40››Issue (7): 526-529.doi:10.3760/cma.j.issn.1673-422X.2013.07.016

Previous ArticlesNext Articles

Advances in the the epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy for lung cancer treatment

ZHANG Bei-Bei, SONG Zheng-Bo, ZHANG Yi-Ping

  1. Chemotherapy Center, Zhejiang Cancer Hospital, Hangzhou 310022, China
  • Online:2013-07-08Published:2013-07-08
  • Contact:ZHANG Yi-Ping E-mail:zyp@medmail.com.cn

Abstract:Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) show good efficacy for the lung cancer patients with EGFR mutations. Chemotherapy drugs are the first choices for the lung cancer patients with EGFR wild-type. In basic research, EGFR-TKIs combination with chemotherapy drugs show good synergy. But in clinical research, the timing of EGFR-TKIs combination with chemotherapy drugs is related to the efficacy.

Key words:Receptor, epidermal growth factor,Drug therapy,Lung neoplasms